You may have seen the story splashed all over the news (e.g. here's an article in the Guardian) highlighting the remarkable response of a patient with advanced breast cancer to T-cell immunotherapy treatment that was given in combination with interleukin-2 and checkpoint blockade.
You can read the original research article published in Nature Medicine here.
But behind the euphoria, researchers are more cautious. The treatment has only proved itself in one woman and that the clinical trials are needed to see how effective the therapy could be in other cancer patients. As we are all too aware, immunotherapies give hugely variable responses between different patients.
This is why the cancer-immune setpoint is so important - offering an innovative way of collating of all of the different factors involved in how a tumour responds to immunotherapy treatment.
But we need your help to keep this valuable resource updated! Pleaseto add or comment on existing factors – or suggest new ones. To help get you started, please follow our a simple step-by-step guide in our .
Reference: Zacharakis et al., Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nature Medicine, published online 04 June 2018: https://www.nature.com/articles/s41591-018-0040-8